SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the
rollout of effective vaccines. Therefore, it is essential to understand the levels of protection …

The risk of coronavirus disease 2019 (COVID-19) and disease progression among patients
using immunomodulatory therapy is unclear. Accordingly, we implemented an active …

In this investigation we examined the magnitude, breadth, and durability of SARS-CoV-2
specific antibodies in two distinct B-cell compartments: long-lived plasma cell-derived …

… Amanda E. Brunton … Messer, Stephen E. Spurgeon; Cellular and humoral immune
response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia …

We tested human sera from large, demographically balanced cohorts of BNT162b2 vaccine
recipients (n= 51) and COVID-19 patients (n= 44) for neutralizing antibodies against SARS-…

Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with
Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less …

Rationale Longitudinal epidemiological and clinical data are needed to improve the
management of patients with bronchiectasis developing nontuberculous mycobacterial (NTM) …

Rationale: Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis.
However, the long-term natural history of patients with NTM and bronchiectasis is not …

Background Mycobacterium abscessus is the second most common nontuberculous
mycobacterium respiratory pathogen and shows in vitro resistance to nearly all oral antimicrobials. …

The unprecedented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
has called for substantial investigations into the capacity of the human immune system to …